抗系统性红斑狼疮新药贝利单抗的药理作用及临床评价

Pharmacological effects and clinical evaluation of belimumab in treatment of systemic lupus erythematosus

贝利单抗是一种人源化IgG1λ单克隆抗体,用于成人红斑狼疮患者中正在接受标准治疗(包括类固醇皮质激素、抗疟药、免疫抑制剂和非甾体抗炎药)的活动性、自身抗体-阳性的系统性红斑狼疮的治疗。现对其药理作用、药动学、临床及安全性评价和药物相互作用等做一综述。

Belimumab,a monoclonal antibody against human IgG1λ,is used for the treatment of adult patients with active,autoantibody-positive,systemic lupus erythematosus（SLE）,who are receiving standard therapy（including corticosteroids,antimalarials,immunosuppressive agents and non-steroidal anti-inflammatory drugs）.In this review,we summarized the pharmacological effects,pharmacokinetics,clinical evaluations,side effects and drug interactions of belimumab.